The inability to get enough oxygen into the lung raises the risk for developing hypoxia. Hypoxia is a condition where not enough oxygen makes it to the cells and tissues in the body. This can happen even though blood flow is normal. Hypoxia is caused by several pulmonary disorders like COPD, Pneumonia, Cystic Fibrosis.

According to the World Health Organization, 35 million people suffer hypoxia worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.

It is estimated that at least 13.3% of children with pneumonia have hypoxaemia, corresponding to 1.86 million cases of hypoxaemic pneumonia each year.


Aodh Lifesciences developed Oxygen Nanobubbles. The nanobubbles are injected intravenously, flow through the blood and offload the oxygen to hemoglobin to increase blood oxygen levels. Oxygen nanobubbles are intended to deliver sufficient oxygen to patients suffering from hypoxia, hypoxic solid tumors, stroke, sickle cell crisis, hemorrhagic shock, traumatic brain injury, and myocardial infarction. Preclinical studies have shown promising results in Tracheal occluded hypoxic rat models.